America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
How does AOH1996 selectively target cancer cells without harming healthy cells?
**Interview with Dr. Linda Malkas on Groundbreaking Cancer Drug AOH1996**
**Interviewer:** Thank you for joining us, Dr. Malkas. You and your team at City of Hope have made significant strides in cancer treatment with the development of AOH1996. Can you explain the key mechanism of this drug?
**Dr. Linda Malkas:** Thank you for having me. AOH1996 utilizes a unique approach known as ‘targeted chemotherapy.’ Essentially, this drug is designed to selectively disrupt the reproductive cycle of cancerous cells by targeting a mutant variant of the PCNA protein. Think of it like a blizzard that halts flights at an airline’s hub—this drug effectively stops the flow of cancer cells, leaving healthy cells unharmed.
**Interviewer:** That’s a fascinating analogy! Over what timeframe has this drug been developed, and which types of cancers has it shown promise in treating?
**Dr. Linda Malkas:** The development of AOH1996 has spanned almost two decades. During clinical trials, it has shown effectiveness against various types of cancer, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. We rigorously tested it on over 70 cancer cell lines, and the results have been very encouraging.
**Interviewer:** What are the next steps for AOH1996 after these promising results?
**Dr. Linda Malkas:** The next critical step is to advance our findings to clinical trials in humans. This phase will help determine the drug’s safety and efficacy in a clinical setting, which is crucial for approving it for widespread use.
**Interviewer:** Given your expertise in molecular diagnostics, how does the mutation in PCNA specifically provide a target for this treatment?
**Dr. Linda Malkas:** Excellent question. PCNA is a protein crucial for DNA replication and tumor growth. In cancer, this protein undergoes unique mutations that differentiate it from its normal counterpart. By specifically targeting these mutations, AOH1996 can selectively kill cancer cells while minimizing damage to healthy tissue.
**Interviewer:** Thank you for sharing your insights, Dr. Malkas. We look forward to seeing how AOH1996 progresses in clinical trials and its potential impact on cancer treatment.
**Dr. Linda Malkas:** Thank you for the opportunity to discuss our work. We’re optimistic about the future!
